These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26043724)

  • 21. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
    De Backer W; De Backer J; Vos W; Verlinden I; Van Holsbeke C; Clukers J; Hajian B; Siddiqui S; Jenkins M; Reisner C; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2673-2684. PubMed ID: 30214185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
    Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
    Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative contributions of emphysema and airway remodelling to airflow limitation in COPD: Consistent results from two cohorts.
    Tho NV; Ryujin Y; Ogawa E; Trang le TH; Kanda R; Goto K; Yamaguchi M; Nagao T; Lan le TT; Nakano Y
    Respirology; 2015 May; 20(4):594-601. PubMed ID: 25788016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD.
    Snell N; Foster M; Vestbo J
    Respir Med; 2013 Nov; 107(11):1722-30. PubMed ID: 23827726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
    Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
    Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD.
    Ramlal SK; Visser FJ; Hop WC; Dekhuijzen PN; Heijdra YF
    Pulm Pharmacol Ther; 2014 Aug; 28(2):158-64. PubMed ID: 24076367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease.
    Yasui H; Inui N; Furuhashi K; Nakamura Y; Uto T; Sato J; Yasuda K; Takehara Y; Suda T; Chida K
    Pulm Pharmacol Ther; 2013 Jun; 26(3):336-41. PubMed ID: 23340058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease.
    Campbell M; Eliraz A; Johansson G; Tornling G; Nihlén U; Bengtsson T; Rabe KF
    Respir Med; 2005 Dec; 99(12):1511-20. PubMed ID: 16199148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease.
    Leidy NK; Murray LT; Jones P; Sethi S
    Ann Am Thorac Soc; 2014 Mar; 11(3):316-25. PubMed ID: 24432712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials.
    Maleki-Yazdi MR; Singh D; Anzueto A; Tombs L; Fahy WA; Naya I
    Adv Ther; 2017 Jan; 33(12):2188-2199. PubMed ID: 27796912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
    Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
    Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
    Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG
    Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
    Singh D; Magnussen H; Kirsten A; Mindt S; Caracta C; Seoane B; Jarreta D; Garcia Gil E
    Pulm Pharmacol Ther; 2012 Jun; 25(3):248-53. PubMed ID: 22497752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ; Yoon HK; Park MJ; Yoo KH; Jung KS; Park JW; Lim SY; Shim JJ; Lee YC; Kim YS; Oh YM; Kim S; Yoo CG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1589-1596. PubMed ID: 28615931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
    Rennard SI; Schachter N; Strek M; Rickard K; Amit O
    Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.